The clinical utility of gene testing for alzheimer's disease

12Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Alzheimer's disease (AD) is the largest cause of dementia, affecting 35.6 million people in 2010. Amyloid precursor protein, prese-nilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) ε4 is a susceptibility gene for late-onset AD. The genes for phos-phatidylinositol-binding clathrin assembly protein, clusterin and complement receptor 1 have recently been described by genome-wide association studies as potential risk factors for late-onset AD. Also, a genome association study using single neucleotide polymorphisms has identified an association of neuronal sortilin related receptor and late-onset AD. Gene testing, and also predictive gene testing, may be of benefit in suspected familial early-onset AD however it adds little to the diagnosis of late-onset AD and does not alter the treatment. We do not recommend APOE ε4 genotyping. © E.R. Atkins and P.K. Panegyres, 2011.

Author supplied keywords

Cite

CITATION STYLE

APA

Atkins, E. R., & Panegyres, P. K. (2011). The clinical utility of gene testing for alzheimer’s disease. Neurology International, 3(1), 1–3. https://doi.org/10.4081/ni.2011.e1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free